胶质瘤循环生物标志物综述
本文叙述性综述了胶质瘤患者循环生物标志物的现有证据,涵盖循环肿瘤细胞、游离DNA、microRNA、外泌体及血液和脑脊液蛋白等,讨论了发现方法的优势与挑战及潜在临床应用,但目前尚无经验证的胶质瘤循环生物标志物检测。
要点
- 目前尚无经验证的胶质瘤循环生物标志物检测。
- 已研究标志物包括循环肿瘤细胞、cfDNA、microRNA、外泌体和蛋白。
- 循环生物标志物潜在用于筛查、分型、监测和个体化治疗。
核心结论
- 尽管循环生物标志物在多种癌症中取得进展,但目前尚无经验证的胶质瘤循环生物标志物检测。
研究设计与样本
- 叙述性综述,汇总胶质瘤患者循环生物标志物的当前证据。
主要发现
- 已检测的循环因素包括循环肿瘤细胞、游离DNA、microRNA、外泌体及外周血和脑脊液蛋白,结果不一。
临床怎么用
- 循环生物标志物潜在应用于人群筛查、肿瘤亚型分类、肿瘤状态监测及基于肿瘤基因分型的个体化治疗。
局限性
- 综述讨论了当前发现方法的优势与挑战,但未报告具体验证数据或阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accurate circulating biomarkers have potential clinical applications in population screening, tumor subclassification, monitoring tumor status, and the delivery of individualized treatments resulting from tumor genotyping. Recently, significant progress has been made within this field in several cancer types, but despite the many potential benefits, currently there is no validated circulating biomarker test for patients with glioma. A number of circulating factors have been examined, including circulating tumor cells, cell-free DNA, microRNA, exosomes, and proteins from both peripheral blood and cerebrospinal fluid with variable results. In the following article, we provide a narrative review of the current evidence pertaining to circulating biomarkers in patients with glioma, including discussion of the advantages and challenges encountered with the current methods used for discovery. Additionally, the potential clinical applications are described with reference to the literature.
引用
- Jones J, Nguyen H, Drummond K, et al. Circulating Biomarkers for Glioma: A Review. Neurosurgery. 2021. PMID: 33442748. doi:10.1093/neuros/nyaa540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。